MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Home・Aktien・Vivani Medical

Vivani Medical

Geschlossen

1.06 0.95

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.04

Max

1.11

Schlüsselkennzahlen
By Trading Economics
Einkommen	-103K -6.6M
Angestellte	37

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+247.22% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	11. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-31M 73M
Vorheriger Eröffnungskurs	0.11
Vorheriger Schlusskurs	1.06

Vivani Medical Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Apr. 2026, 23:17 UTC

Ergebnisse

Samsung Forecasts Record First-Quarter Operating Profit

6. Apr. 2026, 23:00 UTC

Heiße Aktien

Stocks to Watch: Health Insurers, Mawson, Owlet

6. Apr. 2026, 22:13 UTC

Wichtige Markttreiber

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6. Apr. 2026, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6. Apr. 2026, 17:09 UTC

Wichtige Markttreiber

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6. Apr. 2026, 16:56 UTC

Wichtige Nachrichtenereignisse

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6. Apr. 2026, 14:47 UTC

Wichtige Markttreiber

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6. Apr. 2026, 23:58 UTC

Market Talk

Wichtige Nachrichtenereignisse

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6. Apr. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6. Apr. 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6. Apr. 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6. Apr. 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6. Apr. 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6. Apr. 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6. Apr. 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6. Apr. 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6. Apr. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. Apr. 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. Apr. 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6. Apr. 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6. Apr. 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6. Apr. 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6. Apr. 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6. Apr. 2026, 18:36 UTC

Akquisitionen, Fusionen, Übernahmen

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. Apr. 2026, 17:59 UTC

Market Talk

Wichtige Nachrichtenereignisse

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6. Apr. 2026, 17:13 UTC

Akquisitionen, Fusionen, Übernahmen

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. Apr. 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6. Apr. 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Apr. 2026, 14:59 UTC

Ergebnisse

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer-Vergleich

Kursveränderung

Vivani Medical Prognose

Kursziel

By TipRanks

247.22% Vorteil

12-Monats-Prognose

Durchschnitt 3.75 USD 247.22%

Hoch 4 USD

Tief 3.5 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vivani Medical – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vivani Medical – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

Über Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.